Global InformationCirmtuzumab information
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | ROR1 |
| Clinical data | |
| Other names | UC-961 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| UNII |
|
Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.[1][2]
It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).[3][4]
- ^ Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, et al. (2015). "Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts". Blood. 126 (23): 1736. doi:10.1182/blood.V126.23.1736.1736.
- ^ "Researchers to test novel drug combination against toughest breast cancers". Medical Express. 2018-08-27.
- ^ Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
- ^ "1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo". Lymphoma News Today. 2018-05-18.